These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C; J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910 [TBL] [Abstract][Full Text] [Related]
10. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Bissonnette R; Luger T; Thaçi D; Toth D; Messina I; You R; Guana A; Fox T; Papavassilis C; Gilloteau I; Mrowietz U Br J Dermatol; 2017 Oct; 177(4):1033-1042. PubMed ID: 28580579 [TBL] [Abstract][Full Text] [Related]
11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969 [TBL] [Abstract][Full Text] [Related]
12. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis. Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661 [No Abstract] [Full Text] [Related]
14. Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect? Loi C; Patrizi A; Sechi A; Tartari F; Magnano M; Bardazzi F G Ital Dermatol Venereol; 2018 Aug; 153(4):590-591. PubMed ID: 29767491 [No Abstract] [Full Text] [Related]